By: DSM Pharma Solutions Editors
As a global leader in solutions for Nutrition, Health & Sustainable Living, securing a long-term supply of high-quality products for its customers is of utmost importance to DSM. Following substantial investments in China and the opening of the state-of-the-art facility in Xinghuo for vitamin B6 production in 2016, DSM continues to produce the vitamin in their site in Grenzach, Germany. In line with its strategy, DSM will continue to invest in the Grenzach facility to ensure meeting the latest requirements and standards. The site is the only one that produces vitamin B6 in the western world
The two qualified sites, each with a strong environmental health and safety performance, will provide DSM the capability to serve its customers in a more flexible manner, today and in the future.
DSM’s qualifications and capabilities to help register products of its pharma customers in end-markets are expanding. DSM will keep most API registration dossiers, such as the CEP, Japanese DMF, and the open/closed part DMFs for submission in Latin America, Asia Pacific and in the Middle East and Northern African countries, for both sites. DSM will keep a Chinese DMF for Xinghuo and file a US DMF exclusively for the Grenzach site. DSM’s goal is to submit this US DMF by the end of 2020.
With this long-term strategy, DSM expands its portfolio of site source and ensures a reliable, yet flexible, supply of vitamin B6 to customers worldwide.
17 October 2019
2 min read
Stay up-to-date on the latest science, events and market trends